Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralipid for Recurrent Implantation Failure in ICSI
NCT03374163Phase 2Completed
- Sponsor
- King Fahd Medical City
- Start
- Jan 2015
- Primary completion
- Jun 2017
- Modality
- Lipid-based Nanoparticles, Small Molecules
01
Overview
A Phase 2 trial of Intralipid 10% in Recurrent Implantation Failure (RIF), sponsored by King Fahd Medical City. Started Jan 2015; status: completed.
02
Drugs
Intralipid 10%
03
Conditions
Recurrent Implantation Failure (RIF)
Beyond the preview
Go deeper on NCT03374163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03374163.